Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III TrialJ. Clin. Oncol 2020 Dec 17;[EPub Ahead of Print], WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu, YC Wei, YY Liu, C Chen, Y Cheng, R Yin, F Yang, SX Ren, XF Li, J Li, C Huang, ZD Liu, S Xu, KN Chen, SD Xu, LX Liu, P Yu, BH Wang, HT Ma, JJ Yang, HH Yan, XN Yang, SY Liu, Q Zhou, YL Wu
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.